Articles tagged with Heart Failure
A study of 39,367 Swedish men found that eating fatty fish once a week reduced the risk of heart failure by 12%, while consuming more than three servings per week did not show a significant difference. Omega-3 fatty acids in fish oils were also linked to a 33% lower risk of heart failure.
A large study found that eating fatty fish once a week reduces the risk of heart failure in men by 12%, while moderate intake of marine omega-3 fatty acids also has a protective effect. However, no significant benefit was seen with higher intakes of either food group.
Telemonitoring is being integrated into cardiac nursing practice to improve heart failure management. The technology enables nurses to remotely monitor patients' vital signs and provide guidance on lifestyle changes and medication.
A clinical trial found that regular exercise significantly improved the quality of life for patients with chronic heart failure, reducing the risk of death and hospitalization. The study also revealed that exercise was well-tolerated and safe, with participants reporting fewer physical and social limitations.
Aerobic exercise training was associated with a modest reduction in the risk of death and hospitalization in patients with heart failure. The study found that exercise adherence decreased over time, but there was no significant difference in mortality rates between the exercise training group and the usual care group.
Patients with moderate to severe heart failure who exercised regularly had a 11% lower risk of hospitalization or death compared to those who didn't exercise. Exercise also reduced the risk of death from cardiovascular disease and complications related to heart failure.
A new study published in Circulation: Heart Failure found that a larger waist circumference is associated with an increased risk of heart failure in both men and women. The research examined two Swedish population-based studies and found that excess body weight was linked to higher rates of heart failure, regardless of BMI.
A clinical trial found that exercise significantly improves the lives of heart failure patients by improving physical limitations, symptoms, and overall quality of life. The study, which enrolled over 2,300 patients, showed a five-point gain on quality-of-life measures for those who exercised, compared to those who received standard care.
The European Society of Cardiology reports that heart failure is the most prevalent chronic cardiac condition in Europe, with 30 million cases identified. Recent improvements in diagnosis and treatment have led to a significant reduction in mortality rates, but challenges persist in prevention, diagnosis, and treatment.
A new, smaller, and lighter implantable heart pump has been shown to be effective in bridging patients with severe heart failure to eventual transplantation. The device, called a left ventricular assist device (LVAD), was tested on 98 patients and found to improve their quality of life and survival rates.
Researchers at Medical College of Georgia developed novel assays to measure corin and active ANP levels in patients with heart failure. Low corin levels may indicate heart failure or those at risk for the condition.
Researchers at Emory University School of Medicine developed the Health ABC Heart Failure Model to predict risk of new onset heart failure in the elderly. The model, validated with a separate library of patient data, identifies high-risk individuals for targeted interventions.
A Henry Ford Health study found that increasing exercise parameters improves quality of life and reduces hospitalization and death risk in heart failure patients. Patients who exercised for 25 minutes at moderate intensity lowered their estimated risk by 10-25 percent.
Researchers compared two groups of patients with coronary artery disease and severe heart failure, finding that surgical ventricular reconstruction made no difference in key clinical outcomes. The study's findings challenge conventional wisdom that making the heart smaller and more normal makes it stronger.
Researchers have discovered two efficient biomarker applications that promise even earlier diagnosis and improved treatment of heart failure. Biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cystatin C can identify patients at high risk, enabling targeted care and reducing healthcare costs.
A phase II study showed relaxin reduces cardiovascular mortality and shortness of breath in heart failure patients with high blood pressure. The drug also improves other clinical endpoints, including hospital stay and days alive out of hospital.
A large international clinical trial found that surgical ventricular reconstruction did not reduce deaths and hospitalizations in heart failure patients, nor improve quality of life compared to bypass alone. The study, STICH, included 1,000 patients from 96 medical centers in 23 countries.
Researchers found that surgical ventricular reconstruction did not improve patients' survival or quality of life, but increased hospitalization costs. The study compared outcomes between patients who received bypass surgery alone and those with added SVR, revealing no significant difference in quality of life measures.
Heart failure is striking younger African-Americans, with one in 100 developing the condition at an average age of 39, compared to Caucasians in their fifties. The study emphasizes the importance of addressing risk factors like hypertension and obesity in young adults to prevent heart failure.
A study published in CMAJ found that implanted defibrillators offer limited survival benefits for older patients with comorbidities. However, younger patients and those without kidney disease may see a benefit from implantable defibrillators to prevent sudden death. The study analyzed over 14,000 patients with heart failure.
Researchers at Thomas Jefferson University identified a novel signaling pathway mediating aldosterone production, which promotes heart failure. Blocking beta-arrestin-1 could lead to lower aldosterone levels and alleviate negative remodeling processes in the injured heart.
Researchers found significant discrepancies between self-reported fatigue and actigraphy readings, suggesting a link between heart failure, sleep disorders, and impairments in health-related quality of life. The study may lead to different approaches to patients suffering from anergia or 'lack of energy'.
The American Board of Medical Specialties approves a new subspecialty in Advanced Heart Failure and Transplant Cardiology, which will provide high-level care for patients with worsening heart failure. The first certified cardiologists will be trained by 2010, offering improved treatment options and outcomes for heart failure patients.
Researchers found that mice missing the AT1A protein lived significantly longer due to reduced oxidative damage and increased cell survival genes. The study suggests that antagonizing this receptor may also promote human longevity.
A study at Columbia University Medical Center found that experimental heart failure drugs may slow muscle loss in Duchenne muscular dystrophy, a fatal genetic disorder. The new class of drugs targets the same microscopic leak that weakens both skeletal and cardiac muscles.
A new study published by Elsevier found that nearly half of patients with heart failure have problems with memory and other aspects of cognitive functioning. Memory problems, especially short-term memory, were the most common type of cognitive deficit in these patients.
Researchers at UC Davis have discovered a new class of drugs that can reduce heart swelling and reverse heart failure. The study, led by cardiologist Nipavan Chiamvimonvat and entomologist Bruce Hammock, found that the enzyme soluble epoxide hydrolase plays a key role in the development of cardiac hypertrophy.
A study published in JAMA found that intensive treatment guided by N-terminal brain natriuretic peptide (BNP) levels significantly improved hospital-free survival in heart failure patients under 75 years old. However, this benefit was not observed in patients over 75 years old.
A study published in JAMA found that using N-terminal brain natriuretic peptide (BNP) to guide therapy did not improve overall clinical or quality of life outcomes for older patients with heart failure. In contrast, the study showed improved survival rates and reduced hospitalizations for patients receiving BNP-guided therapy.
Prolonged loop diuretic use was linked to increased fracture risk in postmenopausal women, but not to bone mineral density changes or falls. The study suggests that fracture prevention measures may be necessary for women on loop diuretic therapy.
A recent study found that female patients are less frequently treated with evidence-based treatments for heart failure, including ACE inhibitors and beta-blockers. However, the gender of the physician plays a significant role in adherence to treatment recommendations, with male physicians prescribing more complete treatment for female ...
Researchers at Massachusetts General Hospital and University of Pennsylvania found that COX2 in mouse nerve cells plays a crucial role in pain caused by physical insult, while PDE5 inhibition may prevent hypertrophy in the mouse heart. These findings have implications for treating conditions such as postoperative and arthritic inflamma...
Researchers have provided insight into the signaling mechanisms behind high blood pressure-induced heart muscle thickening. A new study found that mice lacking RGS2 developed hypertrophy more rapidly than normal mice, leading to heart failure and death at a young age.
Researchers have found that Viagra amplifies the effects of a protective protein called RGS2, which shields the heart from damage caused by high blood pressure. The study, published in the Journal of Clinical Investigation, provides insights into the biology of RGS2 and its potential as a therapeutic target for heart failure.
A study found that frequent arousals in heart failure patients with central sleep apnea may be due to an underlying arousal disorder rather than CSA. This suggests that preventing arousals from sleep could be a new treatment approach for CSA.
Researchers at Thomas Jefferson University's Center for Translational Medicine successfully reversed heart damage in rats with heart failure using gene therapy. The treatment, which involves administering a peptide called βARKct, inhibited the activation of a kinase that contributes to heart failure deterioration.
The Heart Failure Society of America has developed a consensus statement outlining the structure and process of care provided by heart failure clinics. The clinics aim to reduce mortality and rehospitalization rates while improving quality of life for patients through individualized patient care.
A new study suggests that an implantable hemodynamic monitor can help guide medical treatment in patients with diastolic heart failure, reducing the risk of heart failure events. The device continuously records data on heart function and other key variables, allowing healthcare professionals to make adjustments in medical therapy.
A large international study found that treatment with the medication irbesartan did not reduce the risk of death or hospitalization for cardiovascular causes among patients with diastolic heart failure, nor did it improve quality of life. The study also showed that the medication was safe for patients with the condition.
A study found that older adults taking rosiglitazone had a 15% higher rate of death and 13% greater risk of heart failure compared to those taking pioglitazone. The authors highlight the need to consider all-cause mortality risk in elderly patients, as rosiglitazone's cardiovascular effects may be more pronounced.
Researchers at Medical University of South Carolina present a new theory that may lead to effective heart failure treatments by identifying the role of matrix metalloproteinases (MMPs) in the disease. The study suggests that MMPs, similar to those found in cancerous tumors, contribute to the progression of heart failure, leading to the...
Adults with severe heart failure see an average of 23 providers annually, while those with mild and moderate heart failure see 15.9 and 18.6 providers respectively. Heart failure patients have higher medication rates, with 61 prescriptions written in a year, increasing risk of errors and adverse events.
Researchers have identified a new biomarker for heart failure, resistin, which can independently predict an individual's risk of developing the condition. Resistin levels were found to increase the risk of new-onset heart failure by 38% and were a stronger predictor than other inflammatory markers.
Researchers at Johns Hopkins have identified the chemical step involved in blocking the phosphodiesterase 5 enzyme, which slows down the breakdown of cyclic GMP and contributes to heart failure. The discovery paves the way for targeted drug therapies to stall progression of heart failure and hypertrophy.
Researchers at Emory University School of Medicine found that low concentrations of hydrogen sulfide can protect mice from heart failure. The gas is administered intravenously to treat humans with heart failure, showing promising results in regaining heart function and reducing mortality.
Patients with moderate to severe heart failure who exercise regularly have a lower risk of hospitalization or death, according to a comprehensive study. The study found that exercise led to an 11% reduction in the risk of hospitalization or death for those in the exercise group.
A diuretic has been found to reduce the risk of heart failure in women with a preserved ejection fraction, according to a study published in Circulation. The medication, chlorthalidone, was shown to be effective in reducing the occurrence of heart failure in people with a wide range of left ventricular ejection fractions.
The study found that heart failure hospitalization rates have increased dramatically among seniors in the US, with a 131% rise from 1980 to 2006. This trend is particularly concerning for women, who experienced a higher annual percentage increase rate than men.
A Mayo Clinic study of nearly 3,000 heart attack survivors found that the risk of sudden cardiac death is highest in the first month after leaving the hospital. After that initial period, the risk drops significantly but rises again if symptoms of heart failure appear.
A study found that patients at risk for sudden cardiac death after a heart attack are those who develop heart failure or recurrent ischemia. The risk declines over time, but remains high during the first month after heart attack.
A study of 1,402 fourth-grade students found high diabetes risk factors and obesity rates among children from poor families. Whole-grain intake was linked to lower heart failure risk, while high-fat dairy and egg consumption increased the risk.
A large prospective study found that whole grain consumption lowered heart failure risk, while high-fat dairy and egg intake increased risk. Researchers recommend increasing whole grain intake and reducing high-fat dairy and egg consumption for those at high risk of heart failure.
Researchers found that heart failure patients have a fourfold higher risk of fracture and six times the risk of hip fracture compared to other heart patients. Heart failure and osteoporosis share common risk factors such as older age, female sex, smoking, and type-2 diabetes.
Researchers found that history and physical examinations accurately estimated fluid levels in patients with congestive heart failure. Additionally, those with extra fluid were at increased risk of hospitalization or death within six months.
Researchers at Duke University Medical Center discovered that two common beta-blockers can stimulate a pathway that promotes cell survival and protects heart tissue. The study finds that alprenolol and carvedilol may have greater potential to repair the heart and prevent further damage.
A large study found that ICDs improve longevity without significantly affecting the quality of life for heart failure patients. Researchers monitored patients' quality of life scores over 30 months and found improvements at 3-12 months, but differences diminished over time.
The 2008 ESC guidelines cover acute and chronic heart failure, prioritizing treatment implementation and palliative care. The document identifies gaps in evidence and aims to focus future clinical research on important issues.
The Bach study reveals MR-proANP is equally useful as BNP and NT-proBNP for diagnosing acute congestive heart failure. Adding PCT marker supports differential diagnosis of pneumonia vs. heart failure in patients with shortness of breath.
A randomized controlled trial found that omega-3 polyunsaturated fatty acids (PUFA) reduced mortality and hospital admission for cardiovascular reasons in patients with chronic heart failure. The study involved 357 Italian cardiology sites, with 3494 patients receiving PUFA supplements and 3481 receiving placebo.
A trial of intensified versus standard medical therapy in elderly patients with congestive heart failure found that increased medication doses did not improve outcomes for older adults. In contrast, younger patients showed lower death rates and fewer hospitalizations with intensified therapy.